Vijay Pande
June 10, 2025 08:38 AM EDT
People

For­mer a16z biotech in­vest­ment leader Vi­jay Pande ex­its the VC firm

Kyle LaHucik

Biotech Correspondent

Vi­jay Pande is leav­ing An­dreessen Horowitz af­ter 11 years at the VC firm, he wrote in Mon­day evening posts on LinkedIn …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA's top cell and gene ther­a­py lead­ers ex­it agency in on­go­ing CBER changes

Up­dat­ed: Sage's roller coast­er ends in $561M ac­qui­si­tion by Su­per­nus

Sage sues Bio­gen days af­ter $469M buy­out of­fer

Af­ter a qui­et year, Xaira un­wraps some of its AI re­search, eye­ing a vir­tu­al cell

How a tai­lored ALS drug could help broad­en rare dis­ease ther­a­pies

sponsored

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

A service from the Financial Times